SCHEMBL19355124

SCHEMBL19355124

CC(CNc1cc(-c2ccc3nccnc3c2)ncn1)c1ccnc2c1OCCO2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 2/20 0.39
FAAH O00519 12/20 0.36
PIK3CA P42336 1/20 0.35
CLK4 Q9HAZ1 5/20 0.34
DYRK1A Q13627 4/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
CLK1 P49759 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17634610 1.00 PRKDC (0.39) PRKDCFAAHPIK3CACLK4DYRK1A
SCHEMBL17634599 0.89 TRPV1 (0.40) PRKDCFAAHCLK4DYRK1AALDH1A1
SCHEMBL15343256 0.89 PRKDC (0.39) PRKDCFAAHCLK4DYRK1AALDH1A1
SCHEMBL17634607 0.87 PRKDC (0.38) PRKDCFAAHPIK3CACLK4ALDH1A1
SCHEMBL20373196 0.87 PRKDC (0.38) PRKDCFAAHPIK3CACLK4ALDH1A1
SCHEMBL15343259 0.85 FAAH (0.39) PRKDCFAAHPIK3CACLK4ALDH1A1
SCHEMBL15339597 0.85 PRKDC (0.44) PRKDCFAAHPIK3CACLK4DYRK1A
SCHEMBL15328390 0.85 PRKDC (0.44) PRKDCFAAHPIK3CACLK4DYRK1A
SCHEMBL17634596 0.84 PRKDC (0.39) PRKDCFAAHPIK3CACLK4DYRK1A
SCHEMBL15343234 0.84 PRKDC (0.42) PRKDCFAAHPIK3CACLK4DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193341-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2018-07-12 US disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK PRKDC 33/4885FAAH 3955/4885PIK3CA 226/4885
US-20180193341-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK PRKDC 33/4885FAAH 3955/4885PIK3CA 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.